Avidity Partners Management’s Vaxcyte PCVX Stock Holding History

Avidity Partners Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,000	Closed	-$868K	–	78
2025 Q1	$868K	Buy	+23,000	New	+$1.84M	0.17%	63
2024 Q3	–	Sell	-284,000	Closed	-$21.4M	–	98
2024 Q2	$21.4M	Hold	284,000	–	–	0.91%	45
2024 Q1	$19.4M	Sell	284,000 -286,137	-50%	-$19.8M	0.63%	51
2023 Q4	$35.8M	Sell	570,137 -186,028	-25%	-$9.66M	1.3%	38
2023 Q3	$38.5M	Sell	756,165 -118,835	-14%	-$5.86M	1.55%	29
2023 Q2	$43.7M	Buy	875,000 +365,000	+72%	+$17.3M	1.53%	24
2023 Q1	$19.1M	Sell	510,000 -1,105,400	-68%	-$46.9M	0.63%	52
2022 Q4	$77.5M	Buy	1,615,400 +986,700	+157%	+$38.7M	1.68%	21
2022 Q3	$15.1M	Buy	+628,700	New	+$15.9M	0.31%	60

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Avidity Partners Management's PCVX Position: Q2 2025 in Review

Avidity Partners Management sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 23,000 shares — an estimated $868K sold.

Avidity Partners Management first reported a position in PCVX in Q3 2022 and held it in 9 quarters. The position peaked at $77.5M in Q4 2022. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Avidity Partners Management reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Avidity Partners Management sold 23,000 Vaxcyte shares in Q2 2025, an estimated $868K.
Avidity Partners Management first reported a position in Vaxcyte in Q3 2022 and held it in 9 quarters.
Avidity Partners Management's Vaxcyte position peaked at $77.5M in Q4 2022.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Avidity Partners Management's 13F filing for Q2 2025, filed 14 Aug 2025.